Breathtec Biomedical Inc. (
CSE: BTH,
OTCQB: BTHCF,
Forum), through its wholly-owned subsidiary
Nash Pharmaceuticals Inc., on Monday stated that that one of its lead compounds for chronic kidney disease (“CKD”) NP-135 showed positive results in a recently completed study investigating its therapeutic effects in a unilateral ureteral obstruction mouse model of kidney fibrosis.
For more on this news, click
here.
Nash Pharmaceuticals recently made news when it announced week that its lead compound for non-alcoholic steatohepatitis NP-160 showed positive results in a recently completed study investigating its therapeutic effects.
FULL DISCLOSURE: Nash Pharmaceuticals Inc. is a paid client of Stockhouse Publishing.